Candidates ／ 7096
StemCell Institute Inc.7096・Pharmaceuticals
NIHON TRIM CO.,LTD. owns 71% (controlling). Of the listed companies with this trait in 2021–22, 1 in 4 was bought in the following four years or so — against 1 in 11 for all listed companies.
Taking every trait together, its score is 4.3x the average — #17 of 3,751. The closest type of deal is buyout by the parent.
Why it looks like past targets
- NIHON TRIM CO.,LTD. owns 71% (controlling)1 in 4 such companies were bought (2.9x the average)
Score by type of buyer
| Type | vs average for the type | |
|---|---|---|
| Buyout by the parent | 7.9x | |
| Management buyout | 0.6x | |
| Private equity | 4.4x | |
| Strategic buyer | 5.1x |
Ownership
Top 10 shareholders
| Holder | Type | Stake | |
|---|---|---|---|
| 株式会社日本トリム | Company | 71.2% | |
| 名古屋中小企業投資育成株式会社 | Company | 1.7% | |
| 山 本 邦 松 | Individual | 0.9% | |
| Supercell Biotechnology Corporation | Company | 0.7% | |
| ステムセル研究所従業員持株会 | Employee/partner plan | 0.7% | |
| 若 松 茂 美 | Individual | 0.5% | |
| 清 水 崇 文 | Individual | 0.5% | |
| 楽天証券株式会社 | Custodian/nominee | 0.5% | |
| 仲 博 之 | Individual | 0.4% | |
| 尾 林 雅 夫 | Individual | 0.3% |
From the annual report for the year to 2026-03-31. Holder types are assigned by name and can be wrong (for example, a founder’s company can look like an operating company). Annual report (PDF, EDINET)
Key figures
- Controlling shareholder (over 50%)
- Yes
- Largest corporate holder
- 71.2%
- Founder family (individuals and their companies)
- 2.7%
- Officers
- 0.8%
- Net cash ÷ market value
- 41%
- ROE
- 5.8%
- Equity ratio
- 33%
This site ranks listed companies by how closely their public filings (annual reports and large-shareholding reports) resemble past tender-offer and MBO targets. It is not a prediction that any company will be bought, is not based on any non-public information, and is not a recommendation to buy or sell. Not investment advice.
Updated 29 Sep 2026 00:48 JST